One area of the market that I think has particularly strong long-term growth prospects is the healthcare sector.
This is due to increasing demand for healthcare products and services, thanks to the combination of population growth, better treatments, increased chronic disease burden, and ageing populations.
In light of this, I think the following three healthcare shares could be great buy and hold options:
CSL Limited (ASX: CSL)
I think this global biotech giant would be a great buy and hold investment option right now. Over the last decade the company has provided its shareholders with market-beating returns, thanks to strong earnings growth driven by the quality of its products and its high level of investment in research and development. The good news is that I believe it is well-positioned to replicate this success over the next decade, especially given its growing plasma collection network and pipeline of potentially lucrative therapies.
Pro Medicus Limited (ASX: PME)
Pro Medicus is a healthcare technology company that provides a full range of radiology IT software and services to hospitals, imaging centres, and healthcare groups worldwide. These include a suite of radiology information systems (RIS), picture archiving and communication systems (PACS), and e-health solutions, which Pro Medicus management believes constitutes one of the most comprehensive end-to-end offerings in radiology. Demand has been strong for its offering, leading to the company posting a 59.4% increase in half-year revenue to $25.3 million and a 79.9% jump in underlying half-year net profit after tax to $9.2 million earlier this year. Due to its sizeable market opportunity, I believe similarly strong growth is possible over the medium-to-long term.
RESMED/IDR UNRESTR (ASX: RMD)
ResMed is a leading developer of sleep treatment products. A recent presentation revealed that there are an estimated 1 billion people impacted by sleep apnoea worldwide. The vast majority of these people are undiagnosed and could be at risk of life-threatening conditions such as chronic daytime fatigue, heart disease, stroke, type 2 diabetes, and depression. I expect more of these undiagnosed cases to be diagnosed over the next decade, which is likely to lead to increasing demand for ResMed’s industry-leading products and services.
And here are two more exciting shares that I think could prove to be outstanding buy and hold investments.
It’s hard to believe what these 2 ASX companies could mean to the digital payments revolution
The Motley Fool’s top tech analyst has spent years studying the huge global trend in which cash and traditional banks give way to new digital payments systems... And now he’s identified the two ASX companies he believes are poised to win this multi-trillion-dollar “war on cash.”
If he’s right, these two companies could power your portfolio for years to come. Heck, stock #1 is already up 204% in just the last two years...
While Stock #2 has climbed a stunning 954% just since 2015.
Yet we think the biggest returns look to be still ahead. In fact, our expert is convinced investors who act now could be in for 10X gains (or more). Which means you will want to get the details on these 2 ASX companies as soon as possible.
So click the link below right now! We’ll tell you how to pick up your free copy of this brand new report, “Leave Your Wallet at Home: 2 Stocks for the Digital Payments Revolution”…
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and recommends Pro Medicus Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has recommended Pro Medicus Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.